- Login
- Register & Subscribe
- Language: EN FR DE
Company News
Therapeutic vaccine producer raises €13.1 million
Tuesday 9 March 2010
Location
France
A French producer of therapeutic vaccines for cancer has raised €13.1 million from private and public sources in order to bring its lead product, a therapeutic human papillomavirus vaccine, into the clinic.
Ark Therapeutics drops Cerepro appeal
Tuesday 9 March 2010
Location
United Kingdom
Ark Therapeutics Group Plc has dropped its appeal against a negative opinion from the European Medicines Agency for its gene therapy for brain cancer, Cerepro. It also announced that it is in talks about a possible takeover of the company. Ark disclosed the developments on 9 March 2010.
Zalutumumab fails to meet primary endpoint of overall survival
Tuesday 9 March 2010
Location
Denmark
Genmab A/S said that its antibody for head and neck cancer, zalutumumab, has failed to show overall survival in a Phase 3 study in which the drug was being tested in combination with best supportive care versus best standard care alone.
Recentin fails to meet primary endpoint in cancer trial
Monday 8 March 2010
Location
United Kingdom
AstraZeneca Plc said that its candidate drug, Recentin (cediranib), for patients with first-line metastatic colorectal cancer, failed to meet its primary endpoint of non-inferiority in progression-free survival in a Phase 2/3 trial.
Roche and Biogen Idec suspend RA trials with ocrelizumab
Monday 8 March 2010
Location
Switzerland
The Roche Group and Biogen Idec of the US have suspended clinical trials of the humanized anti-CD20 monoclonal antibody, ocrelizumab, in four rheumatoid arthritis trials because of safety issues. The drug was in Phase 2 and 3 trials.
Key milestones for BioAlliance in the second quarter
Friday 5 March 2010
Location
France
BioAlliance Pharma SA is looking ahead to three possibly transforming events in the second quarter of 2010 that could secure its standing as a recognised specialty pharmaceutical company in Europe.
Alzheimer’s drug fails at Phase 3
Thursday 4 March 2010
Location
United States
An investigational drug for patients with Alzheimer’s disease, Dimebon (latrepirdine), has failed in a Phase 3 trial because it could not show statistically significant improvements in patients compared with placebo for cognition and global function.
Intercell expects data in 2010 on vaccines against hospital-acquired infections
Wednesday 3 March 2010
Location
Austria
Intercell AG expects to report data in 2010 on two late-stage vaccine candidates against hospital-acquired infections, conditions that have become serious in recent years because of bacterial resistance to marketed antibiotics.
Merck to acquire Millipore for $7.2 billion
Monday 1 March 2010
Location
Germany
Merck KGaA of Germany has made an agreed bid for the US service provider, Millipore Corp, in a transaction valued at $7.2 billion, including net debt. The merged company is expected to have critical mass in bioresearch and bioprocessing.
Ablynx sees clinical progress in 2010
Sunday 28 February 2010
Location
Belgium
Ablynx NV expects that its heavy-chain-only antibody technology will show clinical progress in 2010 from its own and partnered programmes. It also expects to report progress on new delivery technologies.
Select a News Category
Recent Appointments
Catherine Bréchignac to join Sanofi-Aventis board
Monday March 8 2010
Ulf Jönsson joins PharmaDiagnostics
Monday March 8 2010
Jan van Heek appointed non-executive director at Amarin
Monday March 8 2010
Thomas Hecht to become chairman of Cytos Biotechnology
Monday March 8 2010
Benoît Battistelli elected president of the EPO
Monday March 8 2010